Financial News

Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors

Products You May Like

Article content material

VICTORIA, British Columbia — Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Firm) introduced right now the appointment of Dr. Brinda Balakrishnan, M.D., Ph.D., to the Firm’s Board of Administrators efficient June 14, 2021. Dr. Balakrishnan is Group Vice President, Company and Enterprise Improvement of BioMarin Pharmaceutical Inc. (“BioMarin”), a world biotechnology firm that develops and commercializes revolutionary therapies for sufferers with critical and life-threatening uncommon problems. At BioMarin, Dr. Balakrishnan leads initiatives on company technique, mergers and acquisitions, partnering and licensing.

“On behalf of your complete Firm, it’s an honor to welcome Dr. Balakrishnan to Aurinia’s Board of Administrators,” commented Peter Greenleaf, President and Chief Government Officer of Aurinia. “Together with her wealthy expertise in medication, biotech enterprise improvement and the uncommon illness area, we’re desperate to leverage her enter and insights as we proceed in our mission to help and higher deal with folks struggling with uncommon, autoimmune ailments, together with lupus nephritis.”

Article content material

“I’m delighted to hitch the Board of Administrators of Aurinia,” mentioned Dr. Balakrishnan. “The Firm is at an thrilling second in its evolution, and I look ahead to working with the Board and administration crew as Aurinia continues on its mission to serve folks affected by debilitating autoimmune ailments.”

Dr. Balakrishnan has been at BioMarin since 2016. Previous to becoming a member of BioMarin, Dr. Balakrishnan was the co-founder and Vice President of company technique and product improvement at Imaginative and prescient Medicines, Inc., a start-up centered on creating therapies for uncommon ophthalmic ailments. Earlier than Imaginative and prescient Medicines, she spent two years as a guide at McKinsey & Firm within the healthcare follow, serving shoppers throughout small biotech, massive pharma, and healthcare supplier teams on subjects associated to company technique, company and enterprise improvement, and operations. Previous to McKinsey, Dr. Balakrishnan was in enterprise improvement at Genzyme.

Dr. Balakrishnan earned a B.S. diploma from the Massachusetts Institute of Know-how (MIT) in chemical engineering and a Ph.D. from MIT in biomedical engineering and chemical engineering. She additionally earned her M.D. diploma from Harvard Medical Faculty and carried out her medical coaching in inside medication at Beth Israel Deaconess Medical Heart in Boston, a Harvard hospital.

About Aurinia

Aurinia Prescription drugs is a totally built-in biopharmaceutical firm centered on delivering therapies to deal with focused affected person populations which are impacted by critical ailments with a excessive unmet medical want. The Firm’s head workplace is in Victoria, British Columbia, its U.S. industrial hub is in Rockville, Maryland, and the Firm focuses its improvement efforts globally.

View supply model on



Glenn Schulman, PharmD, MPH
Investor Relations & Company Communications, Aurinia

Dana Lynch
Company Communications, Aurinia

Products You May Like